Ordenar

Buscar

19/08/2024 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre
Villamarin, M, Fernández-Hidalgo, N, Viñado, B, González-López, JJ, Rello, P, Escolà-Verg, L. Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; DOI:10.1093/jac/dkae291. PMID:39158195. IF:3.600(Q2/3D).
19/08/2024 Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
Halik, A, Tilgner, M, Silva, P, Estrada, N, Altwasser, R, Jahn, E, Heuser, M, Hou, HA, Pratcorona, M, Hills, RK, Metzeler, KH, Fenwarth, L, Dolnik, A, Terre, C, Kopp, K, Blau, O, Szyska, M, Christen, F, Krönke, J, Vasseur, L, Löwenberg, B, Esteve, J, Valk, PJM, Duchmann, M, Chou, WC, Linch, DC, Döhner, H, Gale, RE, Döhner, K, Bullinger, L, Yoshida, K, Damm, F. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients. Journal of Hematology & Oncology. 2024; 17(1)DOI:10.1186/s13045-024-01590-1. PMID:39160538. IF:40.400(Q1/1D).
19/08/2024 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment
Diaz-Torne, C, Pou, MA, Horne, A, Gasteiger, C, Dalbeth, N. 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD Open. 2024; 10(3)DOI:10.1136/rmdopen-2024-004443. PMID:39160089. IF:4.700(Q1/1D).
19/08/2024 Usefulness of Xpert MTB/RIF and Xpert Ultra to Categorize Risk of Tuberculosis Transmission to Household Contacts
Mol, A, Sánchez-Montalvá, A, Espinosa-Pereiro, J, Aznar, ML, Salvador, F, Bosch-Nicolau, P, de Souza-Galvao, ML, Jiménez, MA, Rodrigo-Pendás, JA, Millet, JP, Saborit, N, Broto, C, Molina, I, Tórtola, T. Usefulness of Xpert MTB/RIF and Xpert Ultra to Categorize Risk of Tuberculosis Transmission to Household Contacts. Open Forum Infectious Diseases. 2024; 11(8)DOI:10.1093/ofid/ofae450. PMID:39165580. IF:3.800(Q1/3D).
16/08/2024 Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.
Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F, CIDP01 Study Investigators. Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2024; 95(9)DOI:10.1136/jnnp-2023-333112. PMID:38729747. IF:(Q/D).
16/08/2024 Utility of applying a diagnostic algorithm in giant cell arteritis based on the level of clinical suspicion
Estrada, P, Moya, P, Narváez, J, Moragues, C, Navarro, V, Camacho, O, Roig, D, Cerdà, D, Heredia, S, Reina, D, Corominas, H. Utility of applying a diagnostic algorithm in giant cell arteritis based on the level of clinical suspicion. MEDICINA CLINICA. 2024; 163(3)DOI:10.1016/j.medcli.2023.11.021. PMID:38278759. IF:2.100(Q2/3D).
13/08/2024 Personalized Medicine in Acromegaly: The ACROFAST Study
Marques-Pamies, M, Gil, J, Sampedro-Nuñez, M, Valassi, E, Biagetti, B, Giménez-Palop, O, Hernández, M, Martínez, S, Carrato, C, Villar-Taibo, R, Araujo-Castro, M, Blanco, C, Simón-Muela, I, Simó-Servat, A, Xifra, G, Vázquez, F, Pavón, I, Rosado, JA, García-Centeno, R, Zavala, R, Hanzu, FA, Mora, M, Aulinas, A, Vilarrasa, N, Librizzi, S, Calatayud, M, de Miguel, P, Alvarez-Escola, C, Picó, A, Salinas, I, Fajardo-Montañana, C, Cámara, R, Bernabéu, I, Jordà, M, Webb, SM, Marazuela, M, Puig-Domingo, M. Personalized Medicine in Acromegaly: The ACROFAST Study. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2024; 110(1)DOI:10.1210/clinem/dgae444. PMID:38943661. IF:5.100(Q1/2D).
13/08/2024 PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT
Montoro, J, Ngoya, M, Kulagin, A, Giebel, S, Broers, AEC, Bramanti, S, Halahleh, K, Pérez-Simón, JA, Solano, C, Ozcelik, T, Blaise, D, Sanz, J, Henriques, M, de Latour, RP, Martino, R, Scheid, C, Fox, L, Gromek, T, Jurado, M, Sakellari, I, Van Gorkom, G, Matteucci, P, Nagler, A, Koc, Y, Glass, B. PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT. Blood Advances. 2024; 8(15)DOI:10.1182/bloodadvances.2024013328. PMID:38810260. IF:7.100(Q1/2D).